Eyes Matter
  • Home
  • Forms
  • Our Team
  • Contact Us
  • Home
  • Forms
  • Our Team
  • Contact Us

Corneal Crosslinking

Eye Surgery
Eyes Matter > Eye Surgery > Corneal Crosslinking

Corneal Crosslinking Surgery

What is Corneal Cross Linking?
C

Corneal Crosslinking with riboflavin is a treatment that increases the stiffness and rigidity of the cornea. This stabilizes the progression of corneal ectasia (such as Keratoconus). Many patients who previously had progressive ectasia have now been treated and followed for up to seven years without evidence of any further change in their condition.

Young corneas are softer than adult corneas. Younger patients diagnosed with keratoconus are higher risk of developing more advanced disease as well as an accelerated progression compared to adult onset disease. Artificial ageing of the cornea in the young keratoconus patient disproportionately and positively impacts the functional disability for these individuals.

Corneal Cross-Linking
How does Corneal Cross-Linking work?

The majority of the cornea layer is made from collagen fibers which are arranged in intersecting bundles. The strength and rigidity of the cornea is partly determined by how strongly the fibers are linked together. Over the course of a lifetime, an individual’s cornea becomes progressively stiffer due to natural cross-linking between these fibers.

Riboflavin (vitamin B2) is a naturally occurring compound which strongly absorbs UV light. By applying riboflavin to the cornea at the same time as exposing it to a UV light source, the riboflavin enhances the cross-linking effect of the UV light and absorbs the light so that the inner layers of the cornea and intra-ocular structures are protected from the any damaging effects of the light rays.

What is Standard Corneal (Epithelium-Off) Cross-Linking?

The cross-linking treatment is carried out with topical anaesthesia (eye drops). The surface epithelial cell layer is removed from the central part of the cornea, and the riboflavin drops applied. Once the riboflavin has penetrated deep in the corneal stroma, the UV light is focused onto the central area of the cornea for 15 minutes.

Afterwards, a bandage soft contact lens is applied. The contact lens is worn for three or four days until the surface epithelial cell layer has re-grown.

During the first few days the eye will be sore and watery. Sometimes there is slight haziness under the epithelial layer for the first few months after treatment, but the vision stabilizes within a month or so of the treatment.

What is Iontophoresis Corneal Crosslinking?

Trans epithelial corneal Cross-Linking (TE-CXL) is an innovative technique to treat corneal ectasia. The Trans epithelial technique is performed without removal of the corneal epithelium (the thin layer covering the cornea). Since this treatment is not invasive, it is very well tolerated, because it involves less eye discomfort and guarantees quicker vision recovery compared to the techniques that require the removal of the epithelium.

Iontophoresis (from iòntos = ion and phòresis = transport, transport of ions) consists of the transfer of molecules, with an ionic charge (among which riboflavin), throughout the tissues to be treated, by means of a low intensity electric field.

Treatment
How is Iontophoresis Crosslinking treatment given?

On the day of the treatment, eye drops are used to temporarily restrict the pupil. The eye and the area around it are cleansed with an antiseptic solution. Anesthetic eye drops are used to further reduce even the slightest feeling of discomfort.
After applying a lid speculum to keep the eye open (called a blepharostat), the Ophthalmologist places an appropriate ring on the cornea of the patient, which is filled with riboflavin (RICROLIN®+).

A low intensity charge allows the riboflavin to enter the cornea. After 5 minutes of iontophoresis, the ring is removed and the treatment with low intensity ultraviolet rays is performed.crosslinking-ribo

How do the different CXL techniques compare?

Epithelium-On CXL with dripped Riboflavin

I personally do not use this technique. It has gained prominence particularly in juveniles because of its simplicity and reduced levels of post operative pain. There is minimal penetration of the riboflavin into the corneal stroma and the riboflavin saturated epithelium acts as a barrier to CXL. There our published high 1 year treatment failure rates (60-100%). Additional preservatives are used in some products to reduce the resistance between individual skin cells and thus improve penetration. This causes large areas of the corneal skin to slough in up to 50% of patients causing pain on a par with the standard epithelium off technique. These are also the cases I would argue are more likely to note a demarcation line in the stroma and achieve the small positive flattening effects that a minority of publications have reported.

Epithelium-On CXL utilising Iontophoresis to deliver riboflavin to the stroma

The riboflavin used in CXL is in fact Riboflavin-phosphate, a charge molecule. An electric current can applied via a well on the cornea to vastly improve the delivery of the riboflavin to through the corneal epithelium (skin) to the underlying stroma. The observed CXL deep demarcation line (CXL effect limit) is 3-4 times as deep as the dripped-riboflavin epithelium-on technique and about 2/3rds the depth obtained with the standard epithelium off technique. It is less painful and recovery takes 1-2 days compared to the standard epithelium off technique which requires 1-2 weeks. The risks of infection are virtually zero as there is usually no skin defect. The risks of infection, haze, scar and 2 lines decreased vision are much lower (not reported….yet!) while because there is less cross linking the risks of continued progression are theoretically somewhat higher.
I reserve this for patients with mild to moderate keratoconus who have good unaided vision in whom the risks associated with standard epithelium off CXL, particularly if they have only one good seeing eye are considered too high. Although the theoretical risks of continued progression are higher with this form of CXL treatment, when using for milder disease there is also a trade off as these Iontophoretic CXL cases are less likely to progress as much as moderate-to-severe disease would. Published literature shows continued progression rates similar to that associated with standard epithelium-off CXL. What is different is that it does not cause regression of keratoconus as it can with the standard epithelium-off technique which is no big loss as they only have this procedure when they are seeing well anyhow.

Epithelium off standard CXL

The skin is removed and the riboflavin dripped on. The post op recovery to baseline vision is usually 1-2 weeks and if you drive to work the glare could impact you for longer. It provides maximal cross linking. 60% experience a flattening response by 1-2 years post op. The risks for moderate progressive keratoconus include a 5% risk of each of the following; scarring, 2 lines decreased vision and continued progression.

The risks for excess scarring include a very steep cornea, a very thin cornea and age over 35. There is a generally respected 400um safety margin where the cornea should be thick enough before starting CXL. In severe cones to avoid or as a prelude to corneal transplantation these corneas are swelled using hypotonic riboflavin after removal of the corneal epithelium, generally it adds about 120um thickness and thus provides the generally accepted barrier to irradiation of the corneal endothelium. It is however reserved for patients who are older, with more severe disease and thus by default the risks of scarring after CXL are also greater in this group.

What variations on the delivery of CXL exist

crosslinking-1

Figure: (A) The side view of the conical shape of keratoconus. (B) the en-fasse or topographic view of keratoconus (C)+ (D) represent two examples of the segmental application of CXL. (C) Topographic guided CXL applies more treatment to the cone and less or no treatment elsewhere on the cornea (D) Alternative topographic techniques apply a large circular standard treatment area (1) and then apply supplemental treatment zones to the most diseased part of the cornea (2) and finally the cone apex (3). In both these cases significant and deliberate over treatment of the most thinned, disease part of the cornea compared to the original standard Dresden protocol (5.4mW/cm2) occurs. The scar rate and deep persistent haze theoretically should be higher but this information is to date not forthcoming in my reading of the literature and therefore I do not advocate its use but look forward to seeing more publications from others on the subject. (E) Uses excimer laser to reshape the cornea immediately prior to standard CXL. The skin (epithelium) is thinner over the apex of a cone. The technique known as trans-epithelial phototherapeutic keratectomy (PTK) uses the skin as a mask so that laser ablation of the diseased stroma preferentially occurs over the cone apex as the laser ablates through to the underlying corneal stroma first. This improves the shape of the cornea, which then undergoes standard CXL. When the epithelium heals it does so with a more uniform thickness. This technique is particularly useful if there is some inherent axial myopia (about one in 10 keratoconus patients), especially in those with highly asymmetric disease.

Variations on Keratoconus

crosslinking-2

Pellucid marginal degeneration can be viewed as a peripheral form of keratoconus. The thinning starts 1mm in from the limbus and can extend in a broad are for about 150 degrees. Corneal topography produces a classic crab claw pattern on extended 12mm measurement maps. It can occur at any age and progress at any rate but generally presents much later (4th-5th decade) and significant further progression takes a decade to occur. It is much less common than the more central occuring Keratoconus and spectacle corrected astigmatism is possible until quite late. There is much less published literature on CXL in PMD as it is rarer and takes longer to define stability but modest positive evidence on both the safety of CXL in PMD and its ability to stabilise the medical condition have been published. Extra care is required not to irradiate the limbus in these patients as there is a theoetical risk of producing Ocular surface squamous neoplasia (OSSN), dysplasia of the limbal self renewing (stem) cells.

Risks
Complications of CXL

For moderate progressive Keratoconus the best pulished literature suggests there is a 5% risk of ech of the following

1. Scar
2. 2 lines of reduced vision (either unaided or best corrected)
3. Continued progression

These risks can be further stratified so that excess risk occurs if

1. Age over 38
2. Great corneal steepness (Kmax (on Pentacam) greater than 58 D)
3. Thinnest corneal pachymetry (Less than 400um)

Clinical Examples of CXL complications
TBA

Am I suitable?

Click here to find out: Perscription test

 

  • Cataract Surgery
  • Corneal Crosslinking
  • Corneal Transplant
  • Diabetic Retinopathy
  • Implant Vision Correction
  • Macular Degeneration
  • Refractive Cataract Surgery
  • Refractive Lens Exchange
  • Retinal Surgery
  • Standard Cataract Surgery
  • Standard Cataract Surgery Plus

FIND US

Eyesmatter Southside Clinic

Level 2, 2042 Logan Road, Upper Mount Gravatt, 4122

INFORMATION

  • Home
  • Who we are
  • Our Team
  • Events
  • EyesMatter News
  • Am I Suitable?
  • Laser Eye Surgery
  • Corneal Transplant
  • Eye Surgery

HOURS

Monday - Friday 08:00 am - 06:00 pm

Saturday - Sunday Closed

CONNECT WITH US

Copyright Eyes Matter 2017. All rights reserved. Web by Keycomm
Privacy Policy | Disclaimer